TB Alliance

Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

TB Alliance announced a collaboration Monday with ZebiAI to discover, develop and deliver “better, faster-acting and affordable” tuberculosis drugs using the Massachusetts-based company’s machine learning platform.

The project joins a trend in global health: artificial intelligence-driven discoveries in recent years include potential Chagas treatments identified through a Drugs for Neglected Diseases initiative collaboration and an MIT-discovered compound that kills a broad range of…

The TB Alliance announced Tuesday the dosing of the first participant in Phase 1 trials of TBAJ-587, its novel diarylquinoline compound that demonstrated a superior preclinical profile against M. tuberculosis, according to the press release.

In other TB news, the UN-backed Medicines Patent Pool announced last week that it has sublicensed patents and know-how relating to the investigational antibiotic sutezolid to the Gates Medical Research Institute. The sublicense gives access to…

The TB Alliance announced this week that the European Commission has granted conditional marketing authorization for its novel tuberculosis compound, pretomanid, in combination with J&J’s bedaquiline and Pfizer’s linezolid to treat adults with treatment-intolerant or non-responsive multidrug-resistant (MDR) and extensively drug-resistant (XDR) disease.

The U.S. FDA approved the use of pretomanid as part of the “BPaL” regimen in August 2019.

The TB Alliance announced last week that it is giving China-based Hongqi Pharma a country license to market its experimental tuberculosis drug pretomanid as part of the three-drug BPaL treatment regimen. The therapy combines J&J’s bedaquiline, pretomanid and linezolid for extensively drug-resistant TB and treatment-intolerant or non-responsive multidrug-resistant TB.

The signing is the TB Alliance’s third partnership for pretomanid manufacturing—the New York nonprofit has also…

Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria announced a deal with Sanofi last week to guarantee to buy 300,000 doses of the French company’s latent TB treatment rifapentine in return for a price reduction from $45.00 to $15.00 per three-month treatment course for public sector buyers in 100 low- and middle-income countries.

The news comes as media reported that India has waived its requirement for local Phase 3 trials for public procurement and has become the…

Pharma companies, donors and activist groups used the run-up to the 50th Union World Conference on Lung Health, which opened today in Hyderabad, to make announcements on TB vaccines and drugs.

GSK and the International AIDS Vaccine Initiative stole the headlines by revealing at the TBScience pre-conference that two doses of their M72/AS01E vaccine candidate in HIV-negative adults with latent TB infection demonstrated overall efficacy of 50 percent in reducing progression to active TB…

The TB Alliance announced last week that a U.S. FDA advisory committee has recommended approval of its tuberculosis drug pretomanid as part of the BPaL regimen—combining J&J’s bedaquiline, pretomanid and linezolid for the treatment of multidrug-resistant and extensively drug-resistant disease.

While the recommendation is non-binding, the FDA takes the committee’s vote into consideration when evaluating new drugs. The final FDA decision on pretomanid (currently in priority review)…

Mentions:

The TB Alliance announced last week that the U.S. National Institute of Allergy and Infectious Diseases is giving it a five-year, $28.4 million translational research grant to produce two new clinical stage TB candidates that could (combined with other novel drugs) treat all forms of tuberculosis in less than two months.

According to the TB Alliance press release, the compounds currently under development modulate protein production and degradation as part of an integrated approach to…

Mentions:

The TB Alliance announced last week that it is giving generics company Mylan a non-exclusive global license to commercialize its experimental TB drug pretomanid in “certain low- and middle-income countries” as part of the BPaL and BPaMZ treatment regimens. The BPaL regimen is a combination of J&J’s bedaquiline, pretomanid and linezolid for extensively drug-resistant TB and treatment-intolerant or non-responsive multidrug-resistant (MDR) TB. The BPaMZ regimen is a combination of…